Cholinergic drugs are effective for cognitive impairment in PD (Aarsland et al., 2002; Ravina et al., 2005), and cholinergic activity can affect the association between CSF α-synuclein levels and cognitive assessments. Here, SNCA is linked to Parkinson disease.